绥美凯的推荐使用剂量

It is an innovative AIDS treatment drug by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It is clinically suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Recommended dosage of Suimeikan:

Adults and teenagers (weighing at least 40kg)

For adults and adolescents, the recommended dose of Trimax is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Administration method: Orally. SuimeiKai can be taken with or without food.

Miss a dose

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

kidney damage

Patients whose creatinine clearance rate is less than 50mL/min are not recommended to take Suimeikai.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Trimax is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

children crowd

The safety and effectiveness of Suimeikan in children under 12 years of age have not been established. No data yet.

Suimeikai medication for pregnant and lactating women:

pregnancy

In general, decisions should be made to use antiretroviral drugs to treat HIV infection in pregnant women to reduce vertical transmission of HIV. Animal data as well as clinical experience in pregnant women should be considered when considering neonatal risks.

There are no data on the use of Trimax in pregnant women.

Data on the use of dolutegravir in pregnant women are limited or non-existent. The effects of dolutegravir on human pregnancy are unknown. Regarding the coadministration of abacavir and lamivudine in pregnant women, there is a limited amount of data indicating no teratogenic toxicity (more than 400 results from first-trimester exposure). Regarding lamivudine, extensive data (more than 3000 results from first-trimester exposure) indicate no teratogenic toxicity. Regarding abacavir, a certain amount of data (more than 600 results from first-trimester exposure) suggests no teratogenic toxicity.

In animal reproductive toxicity studies, dolutegravir was found to cross the placenta. Animal studies have not shown any direct or indirect harmful effects in terms of reproductive toxicity. Abacavir and lamivudine may inhibit cellular DNA replication, and abacavir has been shown to be carcinogenic in animal models. The clinical significance of these results is unclear.

Trimax should be used during pregnancy only if the expected benefits outweigh the risks to the fetus.

If a patient coinfected with hepatitis B virus is receiving lamivudine-containing medicines, such as Trimax, and subsequently becomes pregnant, the possibility of hepatitis recurrence should be considered when discontinuing lamivudine.

mitochondrial dysfunction

Nucleosides and nucleoside analogs have been shown to cause varying degrees of mitochondrial damage in vitro and in vivo. Mitochondrial dysfunction has been reported in HIV-negative infants exposed to nucleoside analogues in utero and/or postnatally.

breastfeeding

It is unclear whether dolutegravir is secreted into human milk. Existing animal toxicology data shows that dolutegravir can be secreted into milk. Lactating rats received 50 mg/kg dolutegravir orally on day 10 postpartum. The concentration of dolutegravir detected in milk is usually higher than that in blood.

Abacavir and its metabolites are excreted into the milk of lactating rats. Abacavir is also excreted in human milk.

Based on data from more than 200 mother/child pairs receiving HIV treatment, serum concentrations of lamivudine in infants breastfed by mothers receiving HIV treatment are extremely low (less than 4% of maternal serum concentrations) and tend to decrease gradually, reaching undetectable levels by the time the infant reaches 24 weeks of age. No safety data are available for infants younger than 3 months of age receiving abacavir and lamivudine.

It is recommended that HIV-infected women should not breastfeed their infants under any circumstances to avoid transmitting HIV.

fertility

There are no data on the effects of dolutegravir, abacavir, or lamivudine on male or female fertility. Animal studies have shown that dolutegravir, abacavir, or lamivudine has no effect on male or female fertility.

The above is the relevant introduction to the recommended dosage. For more details, please consult your medical companion.